Inventurus Knowledge Solutions Ltd
IKS NSE
Inventurus Knowledge Solutions Ltd
Information TechnologyNSE: IKS BSE: 544309 IT - Services
Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]
AI Verdict: BUY Confidence: 7%
IKS delivers exceptional growth with 46% sales CAGR over 3 years and 40% ROE, justifying a premium valuation. However, the stock trades at 13x book value with zero dividend payout, warranting caution. With 86% analyst buy ratings and strong profit momentum of 49% TTM growth, the risk-reward favors accumulation at current levels.
Key Fundamentals
SmallcapIT Enabled ServicesInformation TechnologyMarket Cap
₹29,329 Cr
Volatility
Moderate
P/E Ratio
40.54
EBITDA
₹1,082 Cr
Debt to Equity
0.74
Book Value
₹163.13
52W High
₹1,777
52W Low
₹1,262
Technical Indicators
Key Insights
Strengths
2- Company has delivered good profit growth of 34.2% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 37.0%
Weaknesses
2- Stock is trading at 13.2 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
Growth Rate
Revenue Growth
18.16% ↗
Net Income Growth
44.94% ↗
Cash Flow Change
51.54% ↗
ROE
-15.13% ↘
ROCE
22.60% ↗
EBITDA Margin (Avg.)
12.63% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 1d agoBUY
Risk high
IKS delivers exceptional growth with 46% sales CAGR over 3 years and 40% ROE, justifying a premium valuation. However, the stock trades at 13x book value with zero dividend payout, warranting caution. With 86% analyst buy ratings and strong profit momentum of 49% TTM growth, the risk-reward favors accumulation at current levels.
Bull Case 8
- Exceptional 3-year compounded sales growth of 46% CAGR far exceeds IT sector median of 15-20%
- ROE of 40% in the last year indicates highly efficient capital allocation and strong moat
- 5-year compounded profit growth of 34% CAGR demonstrates sustained earnings momentum
- 85.71% analyst buy rating with 6 out of 7 analysts recommending buy signals strong institutional conviction
- TTM profit growth of 49% shows accelerating earnings trajectory over recent quarters
- 3-year ROE consistency at 37% and 5-year at 39% indicates durable competitive advantages
- Market cap of Rs 29,716 Cr positions IKS as a mid-cap with significant room for re-rating as it scales
- Zero analyst sell ratings out of 7 total ratings reflects unanimous positive sentiment
Bear Case 8
- P/B ratio of 13x book value is extremely stretched even for a high-growth IT company, limiting margin of safety
- PE ratio of 40.2x is demanding and prices in near-perfect execution with little room for disappointment
- Zero dividend yield despite repeated profitability suggests poor shareholder return policy
- TTM sales growth deceleration to 20% from 3-year CAGR of 46% signals potential growth slowdown
- Limited trading history with 52-week high and low data unavailable makes technical risk assessment difficult
- Debt-to-equity, EPS, and ROCE data unavailable raises concerns about financial transparency and data coverage
- Stock CAGR of only 5% over 1 year versus 49% profit growth indicates market has already priced in future earnings
- Concentrated analyst coverage with only 7 total ratings implies limited institutional tracking and potential liquidity risk
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 14h ago Positives 1
- Shareholders approve key resolutions May 30
Shareholders approved resolutions for material subsidiary transactions and guarantees with over 99.66% of votes cast in favour, signaling strong investor alignment with management strategy.
Neutral 1
- Investor meet scheduled Jun 8 Jun 1
IKS will host an Analyst and Institutional Investor Meet on June 8, 2026 at Grand Hyatt, Mumbai from 09:00 AM to 05:00 PM IST.
TL;DR: IKS shows strong shareholder confidence with near-unanimous approval of subsidiary-related resolutions. No visible headwinds in the current news cycle. The upcoming investor meet on June 8 could serve as a catalyst if management shares growth plans or new client wins. Trend is stable with a slight positive lean heading into the event.
Quarterly Results
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 567 | 620 | 640 | 643 | 657 | 724 | 740 | 781 | 815 | 858 |
| Expenses | 405 | 494 | 467 | 454 | 476 | 498 | 502 | 511 | 536 | 563 |
| Operating Profit | 162 | 126 | 173 | 189 | 181 | 226 | 238 | 270 | 279 | 295 |
| OPM % | 29% | 20% | 27% | 29% | 28% | 31% | 32% | 35% | 34% | 34% |
| Other Income | 6 | 15 | 4 | 5 | 27 | 3 | 3 | 4 | 6 | 5 |
| Interest | 26 | 32 | 26 | 22 | 21 | 21 | 18 | 16 | 23 | 13 |
| Depreciation | 19 | 27 | 28 | 28 | 28 | 28 | 28 | 30 | 32 | 34 |
| PBT | 124 | 81 | 122 | 144 | 160 | 180 | 195 | 228 | 229 | 253 |
| Tax % | 18% | 21% | 22% | 21% | 19% | 18% | 22% | 21% | 20% | 19% |
| Net Profit | 102 | 64 | 95 | 113 | 130 | 148 | 152 | 181 | 183 | 206 |
| EPS in Rs | 5.94 | 3.72 | 5.57 | 6.59 | 7.56 | 8.61 | 8.83 | 10.53 | 10.68 | 12 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 529 | 553 | 764 | 1,031 | 1,818 | 2,664 | 3,194 |
| Expenses | 367 | 348 | 466 | 639 | 1,297 | 1,893 | 2,112 |
| Operating Profit | 162 | 205 | 298 | 392 | 521 | 771 | 1,082 |
| OPM % | 31% | 37% | 39% | 38% | 29% | 29% | 34% |
| Other Income | 31 | 16 | 1 | -2 | 40 | 39 | 17 |
| Interest | 7 | 8 | 7 | 6 | 61 | 91 | 70 |
| Depreciation | 40 | 30 | 23 | 25 | 59 | 113 | 124 |
| PBT | 145 | 183 | 269 | 359 | 442 | 606 | 905 |
| Tax % | 5% | 9% | 13% | 15% | 16% | 20% | 20% |
| Net Profit | 137 | 165 | 233 | 305 | 370 | 486 | 722 |
| EPS in Rs | 167 | 200 | 13.61 | 17.86 | 21.68 | 28.33 | 42.03 |
| Div. Payout % | 0% | 12% | 393% | 55% | 0% | 0% | 0% |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 275 | 449 | 630 | 812 | 1,141 | 1,773 | 2,224 |
| Borrowings | 0 | 76 | 65 | 52 | 1,311 | 856 | 766 |
| Other Liabilities | 151 | 53 | 75 | 107 | 411 | 274 | 600 |
| Total Liabilities | 434 | 586 | 788 | 988 | 2,880 | 2,919 | 3,606 |
| Fixed Assets | 36 | 87 | 76 | 59 | 1,833 | 1,790 | 1,863 |
| CWIP | 0 | 0 | 0 | 0 | 3 | 13 | 2 |
| Investments | 1 | 14 | 16 | 32 | 195 | 114 | 361 |
| Other Assets | 397 | 485 | 695 | 898 | 849 | 1,003 | 1,380 |
| Total Assets | 434 | 586 | 788 | 988 | 2,880 | 2,919 | 3,606 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | 163 | 175 | 233 | 288 | 210 | 318 | 674 |
| Investing | -79 | -167 | -82 | -158 | -1,137 | 241 | -210 |
| Financing | -41 | -37 | -59 | -152 | 780 | -389 | -412 |
| Net Cash Flow | 43 | -28 | 92 | -22 | -147 | 170 | 52 |
| Free Cash Flow | 152 | 168 | 222 | 280 | 177 | 276 | 613 |
| CFO/OP | 118 | 100 | 93 | 93 | 58 | 56 | 80 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 49 | 46 | 57 | 73 | 73 | — |
| Cash Conversion Cycle | 51 | 49 | 46 | 57 | 73 | 73 | — |
| Working Capital Days | 20 | 41 | 15 | 21 | -75 | 10 | — |
| ROCE % | — | 47% | 47% | 50% | 30% | 27% | — |
Documents
1
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Q4 FY2025-26 earnings conference call scheduled for May 14, 2026 at 8:30 AM IST. 2d - Q4 FY2025-26 earnings conference call scheduled for May 14, 2026 at 8:30 AM IST.
3
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Apr - Newspaper Advertisement confirming dispatch of Postal Ballot Notice. 29 Apr - Newspaper Advertisement confirming dispatch of Postal Ballot Notice.
4
Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2026.
5 May - Board meets May 13, 2026 to approve audited Q4 and FY26 financial results; trading window closed till May 15. 5 May - Board meets May 13, 2026 to approve audited Q4 and FY26 financial results; trading window closed till May 15.
5
Announcement under Regulation 30 (LODR)-Press Release / Media Release
5 May - IKS Health announces multi-year partnership with Holyoke Medical Center on May 5, 2026. 5 May - IKS Health announces multi-year partnership with Holyoke Medical Center on May 5, 2026.
Frequently Asked Questions about Inventurus Knowledge Solutions Ltd
What does Inventurus Knowledge Solutions Ltd do?
Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]
Where is Inventurus Knowledge Solutions Ltd (IKS) listed?
Inventurus Knowledge Solutions Ltd is listed on the Indian stock exchanges. It is listed on NSE: IKS and BSE: 544309. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Inventurus Knowledge Solutions Ltd belong to?
Inventurus Knowledge Solutions Ltd operates in the Information Technology sector within the IT - Services industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Inventurus Knowledge Solutions Ltd?
Inventurus Knowledge Solutions Ltd has a market capitalisation of approximately ₹29328.72 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Inventurus Knowledge Solutions Ltd?
The Price-to-Earnings (PE) ratio of Inventurus Knowledge Solutions Ltd is 40.54. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Inventurus Knowledge Solutions Ltd?
Over the past 52 weeks, Inventurus Knowledge Solutions Ltd has traded between a low of ₹1,262 and a high of ₹1,777. This range helps investors understand the stock's price volatility and recent trading levels.
How can I research Inventurus Knowledge Solutions Ltd on Tapetide?
On Tapetide, you can view Inventurus Knowledge Solutions Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]
Website ikshealth.com
CEO Mr. Sachin K. Gupta
Employees 7,530
Listed 2024-12-19
Face Value ₹ 1
Issued Size 17,15,73,159